PITTSBURGH and BRIDGEWATER, N.J., April 28, 2025 /PRNewswire/ -- PredxBio, a pioneer in AI-powered spatial biomarker discovery, today announced a...
BOSTON and ROLLE, Switzerland, April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader...
CHICAGO, April 28, 2025 /PRNewswire/ -- New research published in Cancer Research and presented today at the AACR Annual Meeting 2025 shows that...
SPOKANE, Wash., April 28, 2025 /PRNewswire/ -- Gestalt, a leading innovator in AI-powered digital pathology solutions, announced the completion of a...
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies...
Collaboration Projected To Generate Around $10 Million In Revenue Over The Next Three Years NEW YORK, April 28, 2025 /PRNewswire/ --...
New National Survey Reveals How Emotional Isolation Threatens Patient Health LAS VEGAS, April 28, 2025 /PRNewswire/ -- Today, at the Asembia...
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active...
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA®...
New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK,...
ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarterSOLANA BEACH, Calif., April 28, 2025 (GLOBE...
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent PaymentsAntev is developing Teverelix, A...
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025...
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%...
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder...
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of...
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates...
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed...
CrazyBulk CrazyBulk NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Benefits of Legal Steroids for Building Muscle Legal steroids are...